First half results: 21 first loss 3 profit more than 2 billion this burst off the market.

A few days ago, thousands of yam machine received the Shenzhen Stock Exchange on the company's stock termination of the listing decision, data show that thousands of yam machine has nearly 50,000 shareholders, in recent years, the company is deeply involved in annual report fraud, the occupation of funds, and now in the capital market finally ended in de-listing. as of July 21,
, 143 pharmaceutical companies in A-shares reported first-half 2020 results, with more than 50% of the results expected.
Meirui Medical, Xinhecheng, Medicine Mingkang, Changchun Gaoxin, Kyushu Tong and other 12 net profit of more than 1 billion yuan;
in addition, 31 companies are expected to lose, including 21, including American Health, Jipharmaceutical Holdings, ST Tiansheng, Asia Pacific Pharmaceuticals and other losses.
Table 1: Pharmaceutical enterprises in the first half of 2020 performance table 2: pharmaceutical enterprises in the first half of 2020 performance report situation table 3: pharmaceutical enterprises in the first half of 2020 performance forecast statistics as of July 21 21 the first loss is too scary! Two of the two companies with losses of more than $500m, the mine-breaking pit, has nearly 50,000 shareholders in 31 expected losses, including 21 first-time losses, in the pharmaceutical companies that have disclosed their results. among the
, the net profit loss of The New Year Health, Junshi Bio exceeded 500 million yuan, ST Tiansheng, International Medicine, Yihua Health and other 4 decline dissothing more than 10 times.
, Thousand Yams received a decision from Shenzhen Stock Exchange on the termination of the listing of the company's shares.
: This is the company's first loss since its 2015 shell listing.
this year's outbreak of the new crown outbreak, resulting in the United States health of the national medical examination center in February basically unable to open, in March, the local medical examination center under the guidance of the local health department opened one after another, but under the pressure of the epidemic control that the month income level is still low;
due to the large size of the National Medical Examination Center, some fixed costs such as housing rent, staff wages, financial expenses, equipment depreciation and decoration amortization base is still large, resulting in a significant decline in year-on-year performance.
for the performance of the loss, a few days ago, there are investors called the company, the relevant staff said that the current resumption of production, has been restored to about 90%.
Junshi Biology: Recently officially landed on the company, as an innovative driven biopharmaceutical company, Junshi Bio has been committed to the discovery and development of innovative drugs, as well as clinical research and development and commercialization around the world.
the company's expected loss in the first half of this year further expanded, mainly due to the company since its establishment to focus on drug research and development, with JS001's indications expansion and some clinical projectprogress, overseas clinical development, for several years in a row a larger expenditure on research and development costs;
Thousand Yam Machines: Recently, Shenzhen Stock Exchange issued a notice that, because three consecutive years of being issued an unable to express opinion audit reports, Thousand Yam Ause Machine selling shares to terminate the listing;
it is understood that in the 2015-2016 annual report, there are in the case of false reduction of accounts receivable, bad debt provisions, false profit increase, two years of false profits totaled more than 400 million yuan;
the company's net profit loss in recent years totaled more than 3.5 billion yuan, is expected to continue to lose in the first half of this year.
in this regard, Thousand YamS machine said that due to the company and its subsidiaries overdue debt, while being sued by some creditors, and the freezing of part of the company's bank accounts and assets, the company's production and operation and business conditions have a certain impact, the company is expected to 2020 market expansion and production and operation of the slow progress, the beginning of the year to the end of the next reporting period accumulated net profit risk.
"Medical one brother" leader! 12 pharmaceutical companies net profit of more than 1 billion according to statistics, more than 50% of pharmaceutical enterprises in the first half of the results of the positive, 12 net profit of more than 1 billion yuan scale.
, "medical equipment one brother" Meirui Medical ranked first, net profit of up to 3.5 billion yuan;
Meirui Medical: Since the beginning of this year, the new crown epidemic swept the world, the first half of the company in the life information and support line of monitor, ventilator, infusion pump and medical imaging line of portable color super, mobile DR demand increased significantly, of which the life information and support production line pull effect is particularly significant.
starting in the second quarter, the company began to export new crown antibody reagents to overseas markets, making up for some of the impact of the outbreak on in vitro diagnostic production lines.
in addition, the company continued to strengthen internal management, improve operational efficiency, and was affected by the impact of marketing promotion and reduced travel during the outbreak period, operating results showed healthy and healthy growth.
Xincheng: First-half net profit of 2.196 billion to 2.311 billion yuan, up 90% to 100% YoY.
for the growth in performance, XinheCheng said the company's vitamin A, vitamin E, biotin and other products sales prices and sales increased year-on-year.
, Xinhecheng's share price hit a new high, with more than 10 trading days in the past month hitting a new record.
brokerage analysis pointed out that overseas giants stop production and upgrade, increase demand, vitamins, methionine and other business climate upward, overlay the company's production capacity release of a number of new projects, the second half of the performance of the high probability of continuing high growth.
Yingke Medical: In July 2017, it officially landed on A-shares, with a net profit of only 145 million yuan for the year of listing, while the net profit of British Medical in the first half of this year increased by more than 25 times year-on-year, a record high.
Yingke Medical said that the results of a substantial increase, first, affected by the new crown outbreak, the global surge in demand for disposable protective gloves, the company's one-time protective gloves product selling prices have increased significantly, making sales revenue and gross margin have increased;
3 is the Office of the United States Trade Representative to exempt a variety of medical products imported from China from import duties, including the company's main product butyl gloves, the exemption of related tariffs is conducive to further increase the export competitiveness of the company's products, improve the company's overall profitability.
Fourth is the company's trade in masks, isolation clothing and other protective supplies sector growth, but also to the performance growth and gross margin increase play a certain role in promoting.
Drug Mingkang: The company's first-half revenue was RMB7.231 billion, up 22.68 percent year-on-year, while net profit was RMB1.717 billion, up 62.49 percent year-on-year, close to the 1.855 billion yuan level for the whole of last year.
said the company was gradually returning to normal operations from the new crown and achieving strong growth in the second quarter.
China laboratory and contract research and development and production business (CDMO) in the second quarter fully resumed normal operations.
at the same time, with the rapid growth of overseas customer orders, as well as the company's production capacity utilization and operating efficiency continue to improve.
's Clinical Trial Services (CRO) and Field Management Services (SMO) businesses are also in the midst of a gradual recovery since the second quarter.
source: Oriental Fortune Network, listed company announcement if there is a mistake, please point to the positive.
original title: 143 pharmaceutical companies sun first half report card! Twenty-one first-loss, three earning more than $2 billion, the mine-breaking pit cry nearly 50,000 shareholders.